Neurizon Therapeutics (ASX: NUZ) has completed an initial drawdown of approximately $8.3 million in non-dilutive capital under its R&D financing facility with the Dare Capital Loan Fund, with the drawdown finalised on 11 August 2026.
The funds are directed primarily toward the pivotal Phase 2/3 HEALEY ALS Platform Trial, with the drawdown secured against the Company’s FY2026 R&D Tax Incentive rebate. The facility provides access to non-dilutive funding of up to $17.5 million in total, allowing Neurizon to bring forward the value of its expected rebate while minimising shareholder dilution.
Deal terms and how the facility works
The facility is structured as a secured, non-dilutive loan against Neurizon’s R&D Tax Incentive rebate, first outlined in the Company’s ASX announcement dated 31 July 2026. Rather than issuing new shares, the Company borrows against a future government rebate, with repayment triggered once that rebate is received.
The $8.3 million first drawdown represents the initial tranche only, secured against the FY2026 rebate. The total facility ceiling of up to $17.5 million includes annual extension options covering the Company’s FY2027 and FY2028 R&D Tax Incentive claims.
Key terms of the facility include:
-
First drawdown: approximately $8.3 million, secured against the FY2026 R&D Tax Incentive rebate
-
Total facility available: up to $17.5 million
-
Interest: 1.25% per month, capitalising monthly
-
Repayment: triggered upon receipt of the R&D Tax Incentive refund from the Australian Taxation Office (ATO)
-
Extension options covering FY2027 and FY2028 R&D claims
The table below summarises the key features of the facility alongside their relevance to shareholders.
| Facility Feature | Detail | Investor Impact |
|---|---|---|
| Initial drawdown | ~$8.3 million | Immediate near-term funding for clinical activities |
| Total facility ceiling | Up to $17.5 million | Additional capacity available via FY2027 and FY2028 claims |
| Security | FY2026 R&D Tax Incentive rebate | Backed by an expected government rebate, not equity |
| Interest terms | 1.25% per month, capitalising monthly | Cost of capital repaid on receipt of ATO refund |
| Dilution impact | Non-dilutive | Existing shareholder ownership is not reduced |
When big ASX news breaks, our subscribers know first
What the funding means for shareholders
The defining feature of this drawdown is its non-dilutive nature. Existing shareholders retain their ownership stake while the Company funds its lead drug candidate, NUZ-001, through the pivotal ALS trial, without issuing new equity.
Management has framed the drawdown as reducing reliance on alternative funding sources, including the Obsidian convertible note facility. This represents a tangible execution of Neurizon’s stated capital management strategy, which aims to align capital availability with key clinical milestones.
The Obsidian convertible note facility was structured as a milestone-aligned instrument designed to minimise upfront dilution while maintaining financial flexibility, forming part of the broader $44.2 million funding package Neurizon assembled ahead of Phase 2/3 trial entry.
CFO Commentary
“Completing this drawdown is a tangible and positive step in the execution of our capital management strategy. Accessing approximately $8.3 million of non-dilutive capital earned through our investment in the HEALEY ALS Platform trial strengthens our near-term funding position while reducing our reliance on alternative sources of capital. The facility enables us to bring forward the value of our expected R&D Tax Incentive rebate and continue investing in the development of NUZ-001 as we progress toward the anticipated HEALEY topline readout in late Q2 CY2027.” said Mr Dan O’Connell, Chief Financial Officer.
Understanding non-dilutive R&D financing
A non-dilutive R&D financing facility allows a company to borrow against a future government R&D Tax Incentive rebate rather than issuing new shares to raise money. This contrasts with dilutive capital raises such as share placements or convertible notes, where new shares are created and issued.
The distinction matters for a pre-revenue biotech like Neurizon:
-
Placements and convertible notes: raise cash by issuing new shares, diluting existing holders
-
Non-dilutive R&D financing: raises cash against a future rebate, leaving share ownership intact
For a company funding an expensive clinical trial before generating revenue, non-dilutive capital allows that trial to progress without eroding shareholder ownership.
The HEALEY ALS Platform Trial and the road ahead
Proceeds from the drawdown will support Neurizon’s continued investment in the pivotal Phase 2/3 HEALEY ALS Platform Trial, which is evaluating the Company’s lead candidate, NUZ-001. The trial is now fully recruited, marking a significant operational milestone as the Company progresses toward its next key catalyst.
The trial expansion to 240 participants was completed without any change to funding requirements, with philanthropic contributions and the Australian R&D Tax Incentive covering incremental costs, and recruitment is now tracking ahead of expectations across 78 activated US clinical sites.
The anticipated topline readout from the trial is expected in late Q2 CY2027. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.
The near-term milestone timeline can be summarised as follows:
-
Phase 2/3 HEALEY ALS Platform Trial, now fully recruited
-
Funding secured to advance the trial (this announcement)
-
Anticipated topline readout, expected in late Q2 CY2027
The drawdown strengthens Neurizon’s near-term funding flexibility as it approaches this key clinical milestone, providing capital to support ongoing trial activities while the Company awaits the anticipated readout.
Don’t Miss the Next Biotech Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare and biotech news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.